Levilimab

DB16387InvestigationalProtein Based Therapies

Levilimab is under investigation in clinical trial NCT04227366 (Study of the Efficacy and Safety of BCD-089 in Combination With Methotrexate in Patients With Active Rheumatoid Arthritis).

Mechanism: Levilimab is an IL-6 inhibitor originally developed to treat rheumatoid arthiritis. Its actions at IL-6 help augment cytokine storm effects, reducing inflammation.
Curator reviewed
Code names: BCD-089

Resolves to

Compound

UNIIP7UV3L2H80CAS2035008-70-7

Clinical / RWD

ATCL04AC25

Targets

P08887IL6R

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

1ATC codeIncluding every combination product, plus 12 drug categories

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Levilimab, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account